CoolSculpting works by taking advantage of the fact that fat cells are more sensitive to cold than the other cells around them. This basic scientific fact was first discovered in 1970 by doctors observing children who sucked on popsicles for hours, and ended up having first soreness, and later dimples, caused by loss of fat cells! Fast forward about 20 years, and Harvard scientists revisited this fact, and realized that they could turn this science into a system for aesthetic sculpting of fatty bulges. The key was to find the ‘sweet spot’ of time and temperature, which would kill some fat cells but not damage surrounding structures such as skin. They called the public company that makes the systems Zeltiq. The proof of the success of this concept and treatment: Zeltiq was bought out by Allergan in 2016 for whopping 2.5 billion! This was the largest sale of a single medical device company in history.
ASAPS formed an ad hoc committee to further investigate the pros and cons of mesotherapy, he says. "We don't know whether it works or not because it is used by a lot of people who inject all kinds of chemicals into the skin," Fodor explains. "Our committee looked at the literature and we found no uniformity to what is being used, how much is being injected, and where it is being injected, so we could not draw any conclusions," he says. That's why ASAPS is conducting a clinical trial at five centers to definitively answer questions about mesotherapy. "We will do some studies with an exact and rigid protocol so we can compare apples to apples, not apples to oranges," he says.
Fodor is more enthusiastic about the LipoSonix technology. "I am very optimistic," he says." I love the results," he says citing as much as a 7-centimeter reduction in waist circumference seen in clinical trials conducted in Mexico. This technology, which uses high-intensity ultrasound waves, beamed about an inch under the skin to break up fatty tissue, has been studied in both pig models and in 33 people in Mexico, he says. The company has applied for FDA status to begin preclinical studies in the U.S. and expects such trials to begin in 2007.
Copyright 2018. All rights reserved. Registered under the Data Protection Act. Registration No. Z4867545, Discounts For Carers as a trading style of We Are Discounts Ltd is authorised and regulated by the Financial Conduct Authority (674691). We Are Discounts Ltd provide an independent service free of charge but will receive a commission from the brokers and creditors they refer you to. We Are Discounts Ltd is a credit broker not a lender. Brinc Services Ltd is an introducer appointed representative for several Insurers, for more information please click here.
1 July 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.